U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Cover of Drugs and Lactation Database (LactMed®)

Drugs and Lactation Database (LactMed®) [Internet].

Show details

Orphenadrine

Last Revision: August 15, 2024.

Estimated reading time: 1 minute

CASRN: 83-98-7

image 403405075 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

No published information is available on the use of orphenadrine during breastfeeding. Manufacturer’s estimates indicate that the amount in milk may be low. The drug’s anticholinergic activity might interfere with milk production. An alternate agent may be preferred.

Drug Levels

Maternal Levels. A European manufacturer of orphenadrine estimated that with a maternal dose of 150 mg, milk orphenadrine concentration would be about 300 to 400 mcg/L.[1] This implies that the relative infant dosage might be about 1.8 to 2.4% of the mother’s weight-adjusted dosage.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Orphenadrine has anticholinergic activity. Anticholinergics can inhibit lactation in animals, apparently by inhibiting growth hormone and oxytocin secretion.[2-6] Anticholinergic drugs can also reduce serum prolactin in nonnursing women.[7] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

References

1.
Chaplin S, Sanders GL, Smith JM. Drug excretion in human breast milk. Adv Drug React Ac Pois Rev 1982;1:255-87.
2.
Aaron DK, Ely DG, Deweese WP, et al. Reducing milk production in ewes at weaning using restricted feeding and methscopolamine bromide. J Anim Sci 1997;75:1434-42. [PubMed: 9250502]
3.
Powell MR, Keisler DH. A potential strategy for decreasing milk production in the ewe at weaning using a growth hormone release blocker. J Anim Sci 1995;73:1901-5. [PubMed: 7592071]
4.
Daniel JA, Thomas MG, Powell MR, et al. Methscopolamine bromide blocks hypothalmic-stimulated release of growth hormone in ewes. J Anim Sci 1997;75:1359-62. [PubMed: 9159285]
5.
Bizzarro A, Iannucci F, Tolino A, et al. Inhibiting effect of atropine on prolactin blood levels after stimulation with TRH. Clin Exp Obstet Gynecol 1980;7:108-11. [PubMed: 6788407]
6.
Svennersten K, Nelson L, Juvnäs-Moberg K. Atropinization decreases oxytocin secretion in dairy cows. Acta Physiol Scand 1992;145:193-4. [PubMed: 1636447]
7.
Masala A, Alagna S, Devilla L, et al. Muscarinic receptor blockade by pirenzepine: Effect on prolactin secretion in man. J Endocrinol Invest 1982;5:53-5. [PubMed: 6808052]

Substance Identification

Substance Name

Orphenadrine

CAS Registry Number

83-98-7

Drug Class

Breast Feeding

Lactation

Milk, Human

Antiparkinson Agents

Cholinergic Antagonists

Muscle Relaxants, Central

Parasympatholytics

Muscarinic Antagonists

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Copyright Notice

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Bookshelf ID: NBK564284PMID: 33226747

Views

Related information

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...